Notice of Receipt of Shareholder Proposals

Overview of Shareholder Proposals

Rohto Pharmaceutical Co., Ltd. has received shareholder proposal documents from shareholders AVI JAPAN OPPORTUNITY TRUST PLC and LONGCHAMP SICAV in relation to the 90th Annual General Meeting of Shareholders scheduled for June 24, 2026. Shareholder Proposal 1 requests the dismissal of one director. Shareholder Proposal 2 includes seven agenda items: establishment of a strategy review committee, amendments to the Articles of Incorporation regarding the decision-making body for dividends of surplus, share buyback, approval of remuneration amounts under the restricted stock remuneration system, amendments to the Articles of Incorporation concerning the composition of outside directors, amendments to the Articles of Incorporation for management measures mindful of capital costs and stock price, and amendments to the Articles of Incorporation related to the record date for the Annual General Meeting of Shareholders.

Future Actions and Impact on Investors

The Board of Directors will carefully examine and deliberate on the shareholder proposals and disclose decisions promptly once made. These proposals involve important matters related to management structure and capital policy, and depending on the resolutions at the shareholders meeting, may affect management policies and governance framework. Investors should pay close attention to forthcoming disclosures.